Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 3/2012

01-06-2012 | Clinical Investigation

Switching the Loaded Agent from Epirubicin to Cisplatin: Salvage Transcatheter Arterial Chemoembolization with Drug-eluting Microspheres for Unresectable Hepatocellular Carcinoma

Authors: Akihiko Seki, Shinich Hori

Published in: CardioVascular and Interventional Radiology | Issue 3/2012

Login to get access

Abstract

Purpose

There is no consensus on switching anticancer agents loaded onto drug carriers in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). This study aimed to evaluate the safety and clinical outcomes of TACE with cisplatin-loaded microspheres (CLM-TACE) in HCC patients refractory to TACE with epirubicin-loaded microspheres (ELM-TACE).

Methods

Between February 2008 and June 2010, 85 patients with unresectable HCC refractory to ELM-TACE were enrolled to undergo CLM-TACE. The number of ELM-TACE sessions until judgment of resistance ranged from 1 to 4 (median, 2.1). CLM-TACE was performed using 50–100-μm superabsorbent polymer microspheres loaded with 1 mg cisplatin/1 mg microspheres together with hepatic arterial infusion of 25 mg cisplatin and 500 mg 5-fluorouracil per patient. Tumor responses were evaluated by computed tomography according to the European Association for the Study of the Liver criteria.

Results

The median number of CLM-TACE treatment sessions was 1.8 (range, 1–5), and the mean total dose of cisplatin per session was 42.8 mg (range, 30.0–59.0). After 6 months, 3 (3.5%) patients achieved complete response, 31 (36.5%) had partial response, 15 (17.6%) had stable disease, and 36 (42.4%) had progressive disease. The median overall survival and time to treatment failure after initial CLM-TACE were 13.3 and 7.2 months, respectively. Overall, 9.4% of patients experienced grade 3/4 adverse events.

Conclusion

Switching the loaded agent from epirubicin to cisplatin is a safe, well-tolerated, and efficacious treatment strategy for salvage TACE with drug-eluting microspheres in HCC patients refractory to ELM-TACE.
Literature
1.
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576PubMedCrossRef
2.
Cottone M, Turri M, Caltagirone M et al (1988) Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alfafetoprotein: a prospective study. Hepatogastroenterology 35:101–103PubMed
3.
Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef
4.
Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442PubMedCrossRef
5.
Llovet JM, Real MI, Montana X et al (2002) Arterial embolization or chemoembolization versus systemic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739PubMedCrossRef
6.
Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25PubMedCrossRef
7.
Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401PubMed
8.
Brown DB, Cardella JF, Sacks D et al (2009) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 20(Suppl 7):S219–S226PubMedCrossRef
9.
Satake M, Uchida H, Arai Y et al (2008) Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 31:756–761PubMedCrossRef
10.
Sonomura T, Yamada R, Kishi K et al (1997) Dependency of tissue necrosis on gelatin sponge particle size after canine hepatic artery embolization. Cardiovasc Intervent Radiol 20:50–53PubMedCrossRef
11.
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481PubMedCrossRef
12.
Hong K, Khwaja A, Liapi E et al (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567PubMedCrossRef
13.
Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342PubMedCrossRef
14.
Jordan O, Denys A, De Baere T et al (2010) Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 21:1084–1090PubMedCrossRef
15.
Maeda N, Osuga K, Higashihara H et al (2010) In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization. J Vasc Interv Radiol 21:877–881PubMedCrossRef
16.
Grosso M, Vignali C, Quaretti P et al (2008) Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicenter study. Cardiovasc Intervent Radiol 31:1141–1149PubMedCrossRef
17.
Seki A, Hori S, Kobayashi K et al (2010) Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol. doi:10.​1007/​s00270-010-9975-y
18.
Poggi G, Amatu A, Montagna B et al (2009) OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 32:1187–1192PubMedCrossRef
19.
Osuga K, Hori S, Hiraishi K et al (2008) Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. Cardiovasc Intervent Radiol 31:1108–1116PubMedCrossRef
20.
Yoshikawa M, Ono N, Yodono H et al (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474–483PubMedCrossRef
21.
Maeda N, Osuga K, Mikami K et al (2008) Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 26:206–212PubMedCrossRef
22.
Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509–522PubMedCrossRef
23.
Kalayci C, Johnson PJ, Raby N et al (1990) Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J Hepatol 11:349–353PubMedCrossRef
24.
Arora AS, de Groen PC, Croall DE et al (1996) Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. J Cell Physiol 167:434–442PubMedCrossRef
25.
Chang JM, Tzeng WS, Pan HB et al (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449–2453PubMedCrossRef
26.
Kawai S, Okamura J, Ogawa M et al (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma: a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 31(suppl):S1–S6PubMedCrossRef
27.
Sahara S, Kawai N, Sato M et al (2010) Prospective comparison of transcatheter arterial chemoembolization with Lipiodol–epirubicin and Lipiodol–cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol 28:362–368PubMedCrossRef
28.
Kawai S, Tani M, Okamura J et al (1997) Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 24(2 suppl 6):S6-38–S6-45
29.
Nicolini A, Martinetti L, Crespi S et al (2010) Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21:327–332PubMedCrossRef
30.
Shen DW, Akiyama S, Schoenlein P et al (1995) Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 71:676–683PubMedCrossRef
31.
Moriguchi M, Takayama T, Nakamura M et al (2010) Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatol Res 40:369–375PubMedCrossRef
32.
Kawaoka T, Aikata H, Takaki S et al (2009) Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol 32:687–694PubMedCrossRef
33.
Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41–52PubMedCrossRef
34.
Kawamura Y, Ikeda K, Hirakawa M et al (2009) Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 39:346–354PubMedCrossRef
Metadata
Title
Switching the Loaded Agent from Epirubicin to Cisplatin: Salvage Transcatheter Arterial Chemoembolization with Drug-eluting Microspheres for Unresectable Hepatocellular Carcinoma
Authors
Akihiko Seki
Shinich Hori
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
CardioVascular and Interventional Radiology / Issue 3/2012
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-011-0176-0

Other articles of this Issue 3/2012

CardioVascular and Interventional Radiology 3/2012 Go to the issue

Letter to the Editor

Strategy of Modern Epistaxis Management

Review Article/State of the Art

Endovascular Renal Artery Denervation: Why, When, and How?

Letter to the Editor

Reverse Chimney or Periscope: Some Issues have to be Addressed “Re: Endovascular Aneurysm Repair Using a Reverse Chimney Technique in a Patient with Marfan Syndrome and Contained Ruptured Chronic Type B Dissection”

Clinical Investigation

Endovascular Treatment in Emergency Setting of Acute Arterial Injuries After Orthopedic Surgery

Laboratory Investigation

A Preclinical Study of the Safety and Efficacy of Occlusin™ 500 Artificial Embolization Device in Sheep

Clinical Investigation

Stereotactic Radiofrequency Ablation (SRFA) of Liver Lesions: Technique Effectiveness, Safety, and Interoperator Performance